Clinical Trials Logo

13-valent Pneumococcal Vaccine clinical trials

View clinical trials related to 13-valent Pneumococcal Vaccine.

Filter by:
  • None
  • Page 1

NCT ID: NCT01193335 Completed - Premature Birth Clinical Trials

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Start date: October 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to describe the safety, tolerability, and immunogenicity of a 2,3,4 and 12 month schedule of the 13-valent pneumococcal conjugate vaccine when given to preterm infants with concomitant vaccines, compared to infants born at term.There will be a follow-up phase to assess the persistence of the antibody response at 24 and 36 months of age.

NCT ID: NCT01026038 Completed - Safety Clinical Trials

Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during infancy in Study 6096A1-008-EU (NCT00366678). In this study, participants will receive an additional dose of 13-valent pneumococcal conjugate vaccine. The purpose of this study is to evaluate persistence, if any, of the antibody response by measuring any remaining pneumococcal antibodies since the previous study. This study will also evaluate the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine when administered at least 24 months after the last dose of pneumococcal conjugate vaccine.

NCT ID: NCT00744263 Completed - Clinical trials for Pneumococcal Infections

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

CAPITA
Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

NCT ID: NCT00743652 Completed - Clinical trials for Pneumococcal Disease

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

Start date: January 2009
Phase: Phase 3
Study type: Interventional

This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.